Method for treating obesity, diabetes, cardiovascular and kidney diseases by regulating gpr30/gper activity
AssigneeStc.Unm
InventorsEric R. Prossnitz, Matthias Barton, Matthias R. Meyer
Life of this patent
Estimating the term…
Abstract
The current invention is in the field of molecular biology/pharmacology and provides methods of using compounds that modulate the effects of GPR30/GPER for treating obesity and diabetes (preferably agonists) as well as disease states and/or conditions that result from excessive formation of reactive oxygen species (preferably antagonists). These compounds may function as agonists and/or antagonists of the disclosed estrogen receptor and/or modulate the expression/upregulation of nox and nox-associated reactive oxygen species (ROS).
Claims25
(canceled)
A method of treating or reducing the likelihood of a disease state or condition in a patient in which excessive production or formation of Nox (NADPH oxidase) isoforms leads to excessive ROS production or formation that mediates said disease state or condition comprising administering to said patient a compound which inhibits and/or reduces the production and/or formation of said Nox (NADPH oxidase) isoforms in said patient.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A pharmaceutical composition comprising an effective amount of a compound which is a GPER/GPR30 modulator or a pharmaceutically acceptable salt thereof, optionally in combination with at least one additional bioactive agent.
(canceled)
-32. (canceled)
Dependencies are inferred from the claim text.